Related Experiment Videos
Oral chemotherapeutic agents for colorectal cancer
1Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. sharma1@mskcc.org
Abstract:
A number of novel oral chemotherapeutic agents are entering practice or are under development in the United States. Many of these agents display significant clinical activity against colorectal cancer. Many classes of compounds, including fluoropyrimidine analogs, dihydropyrimidine dehydrogenase (DPD) inhibitors, topoisomerase inhibitors, farnesyl transferase inhibitors, and others, are being developed for oral administration. This manuscript describes the progress of clinical development of these agents and also explores the relative merits and challenges of these approaches. Economic issues, patient preference, and patient selection issues surrounding oral chemotherapy for colorectal cancer will also be discussed.
Insights
Novel oral chemotherapy agents show promise for treating colorectal cancer. This review covers their development, benefits, challenges, and economic considerations for patient care.
Area of Science:
- Oncology
- Pharmacology
- Gastroenterology
Background:
- Oral chemotherapeutic agents are increasingly important in cancer treatment.
- Colorectal cancer management is evolving with new therapeutic options.
Purpose of the Study:
- To review the clinical development of novel oral agents for colorectal cancer.
- To discuss the advantages, disadvantages, and economic factors of oral chemotherapy.
Main Methods:
- Literature review of ongoing clinical trials and research.
- Analysis of different classes of oral chemotherapeutic compounds.
- Exploration of economic and patient-centered issues.
Main Results:
- Several novel oral agents demonstrate significant activity against colorectal cancer.
- Various compound classes, including fluoropyrimidine analogs and enzyme inhibitors, are under development.
- Clinical progress and challenges of these agents are detailed.
Conclusions:
- Oral chemotherapy offers a promising alternative for colorectal cancer treatment.
- Further research and careful patient selection are crucial for optimizing oral chemotherapy use.
- Economic and patient preference factors significantly influence treatment decisions.